astrazeneca_building_white

AZ’s Tagrisso extends median overall survival by over 3 years in metastatic, EGFR-mutated lung cancer

pharmafile | September 30, 2019 | News story | Research and Development, Sales and Marketing |  AstraZeneca, Cancer, ESMO 2019, Tagrisso, lung cancer, pharma 

AstraZeneca took to the stage at the 2019 European Society for Medical Oncology (ESMO) Congress in Barcelona to present new data on Tagrisso (osimertinib) in the first-line treatment of locally-advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).

Tagrisso was shown to present a “statistically significant and clinically meaningful improvement” in overall survival, extending life by a median of 38.6 months compared to 31.8 months with previous standards of care gefitinib and erlotinib.

After three years of treatment, 28% of Tagrisso patients remained on the first-line study treatment versus just 9% in the study’s comparator arm. Additionally, Tagrisso was shown to reduce the risk of central nervous system disease progression by 52% and extend the length of time patients with CNS metastases lived without CNS disease progression or death.

According to AZ, the drug is the only first-line therapy “to deliver a median overall survival of more than three years” in this indication.

Advertisement

 “Tagrisso has set a new benchmark in EGFR-mutated non-small cell lung cancer by demonstrating a median overall survival of more than three years,” commented José Baselga, Executive Vice President, Oncology R&D.  “We have not before seen survival benefits of this magnitude in any global Phase 3 trial with any such therapy. The ground-breaking data reaffirm the benefit of using Tagrisso first and further support its use as the 1st-line standard of care in this setting.”

Matt Fellows

Related Content

Pharma sees climate disruption as growing supply-chain risk

Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact

In the decade to 2025, AI use in vaccine development has increased markedly but is …

Cizzle Biotechnology expands US rollout of lung cancer blood test

Cizzle Biotechnology has launched the commercial rollout of its CIZ1B Biomarker Blood Test for lung …

The Gateway to Local Adoption Series

Latest content